IL6 and cancer: It should, however, be noted that we used immune‐compromised nude mice with subcutaneous flank implantation of TOV21G, similarly to Zhou et al. who reported the ability of TOV21G to cause cachexia in an activin A‐driven mechanism.5 We acknowledge, however, that activin A may affect both cancer cell‐derived and host‐derived IL‐6 differently in the presence of a complete immune system and when the cancer cells are growing in the pelvic/abdominal cavity.